Compare SXC & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXC | SPRY |
|---|---|---|
| Founded | 1960 | 2015 |
| Country | United States | United States |
| Employees | 2477 | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 762.8M | 788.5M |
| IPO Year | 2011 | 2020 |
| Metric | SXC | SPRY |
|---|---|---|
| Price | $8.98 | $6.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $9.00 | ★ $40.00 |
| AVG Volume (30 Days) | 1.2M | ★ 2.3M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 7.17% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,600,300,000.00 | $84,278,000.00 |
| Revenue This Year | N/A | $87.40 |
| Revenue Next Year | N/A | $81.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.30 | N/A |
| 52 Week Low | $5.52 | $5.77 |
| 52 Week High | $9.74 | $18.63 |
| Indicator | SXC | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 62.87 | 28.16 |
| Support Level | $7.69 | N/A |
| Resistance Level | $9.72 | $8.61 |
| Average True Range (ATR) | 0.27 | 0.44 |
| MACD | 0.09 | -0.18 |
| Stochastic Oscillator | 91.37 | 13.90 |
SunCoke Energy Inc operates as an independent producer of coke in the Americas. Its coke is mainly used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron. The company operates through two segments: Domestic Coke and Industrial Services. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal-producing, and other manufacturing-based customers. The majority of revenue is derived from the Domestic Coke segment.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.